Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTL38 (Cytalux) for Intraoperative Imaging of Lung Nodules
NCT04241315Phase 3Completed
- Sponsor
- On Target Laboratories
- Start
- Mar 2020
- Primary completion
- Oct 2021
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pafolacianine in lung cancer (2 arms), sponsored by On Target Laboratories. Primary endpoints: Clinically Significant Events at 1 day, Localization of Primary Nodule at 1 day and 2 more. Started Mar 2020; status: completed.
02
Drugs
pafolacianine
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT04241315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04241315.